NNP
TAK icon

Nachman Norwood & Parrott’s Takeda Pharmaceutical TAK Stock Holding History

Nachman Norwood & Parrott’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-150
Closed -$3K – 951
2020
Q3 		$3K Buy
+150
New +$2.73K ﹤0.01% 1052

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Nachman Norwood & Parrott's TAK Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Takeda Pharmaceutical (TAK) in Q4 2020, closing a stake of 150 shares — an estimated $3K sold.

Nachman Norwood & Parrott first reported a position in TAK in Q3 2020 and held it in 1 quarter. The position peaked at $3K in Q3 2020. 313 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Takeda Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 150 Takeda Pharmaceutical shares in Q4 2020, an estimated $3K.
  • Nachman Norwood & Parrott first reported a position in Takeda Pharmaceutical in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Takeda Pharmaceutical position peaked at $3K in Q3 2020.
  • 313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.